Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that British Columbia, Non-Insured Health Benefits (NIHB), Nova Scotia, Quebec and Veterans Affairs Canada (VAC) have added WINREVAIR® (sotatercept) to their public drug formularies. As the first jurisdictions to implement public coverage following the completed pan-Canadian Pharmaceutical Alliance (pCPA) agreement, these listings mark an important step toward improving access for Canadians living with pulmonary arterial hypertension (PAH), a rare, progressive and life‑limiting disease.

WINREVAIR® is indicated in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II, III or IV.